Europe Ovarian Cancer Market

Europe Ovarian Cancer Market Size (2022 to 2027)

The size of the Europe Ovarian Cancer Market is estimated to hike at a notable CAGR during the forecast period.

The increasing incidence of ovarian cancer drives the market. In addition, the need for more effective treatment options is pushing the growth of the market. Ovarian cancer is the eighth most commonly occurring cancer in women; hence, the growing geriatric population among women in European countries is expected to augment market growth. Aside from that, rising acceptance of new medicines and a robust development pipeline are expected to boost the European ovarian cancer therapeutics market. An increase in new ovarian cancer cases, the ease of use of new medications and therapies, and increased healthcare spending are driving the ovarian cancer market during the forecast period. 

Epithelial ovarian cancer (EOC), which develops from the ovary's epithelium, is the most prevalent kind of ovarian cancer. Ovarian cancer is one of the most common cancers in women in the Europe region. It kills more women than any other cancer of the female genital system, and it ranks fifth in overall cancer deaths among women. Unfortunately, this type of cancer is rarely diagnosed early, making treatment at a complicated stage difficult. 

Additionally, increasing investment and funding by the government and non-government organizations and technological advancements in the healthcare sector in the developed countries such as Germany, UK, Italy, Spain, and France are accelerating the market growth. 

Generics like paclitaxel and carboplatin dominate the market, although medicines like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to enhance revenue. However, the market may face a challenge in the development of more effective medicines. As a result, discovering new medicines to treat this form of cancer is expected to present substantial market potential.

In the pharmaceutical industry, firms are actively inventing and creating combination medicines to treat ovarian cancer. Combination medicines address complicated medical problems by combining two or more active pharmaceutical ingredients (APIs) into a single dose form.

However, the lack of appropriate technology for early detection of ovarian cancer is a key problem impeding the growth of the European ovarian cancer market. Also, the development of medicine with improved efficacy could pose a challenge for market growth.

This research report on the European ovarian cancer market has been segmented and sub-segmented into the following categories:

By Stage of Cancer:

• Stage I
  • Stage IA
  • Stage IB
  • Stage IC
• Stage II
  • Stage IIA
  • Stage IIB
  • Stage IIC
• Stage III
  • Stage IIIA
  • Stage IIIB
  • Stage IIIC
• Stage IV

By Cancer Type:

• Primary Peritoneal Carcinoma
• Ovarian Stromal Tumors
• Ovarian Germ Cell Tumors
• Epithelial Ovarian Tumors

By Diagnosis:

• Physical Examination
• Blood Tests
• Ultrasound
• PET
• CT Scan
• MRI
• Human Chorionic Gonadotropin Test
• Biopsy

By Type of Treatment:

• Chemotherapy
• Radiation Therapy
• Hormonal Therapy
• Surgery
• Immunotherapy
• Targeted Therapy

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European ovarian cancer market is expected to account for a significant share globally during the forecast period. The factors such as the increasing geriatric population, availability of advanced technology in the healthcare sector, and proliferation of ovarian cancer cases propelling the market growth. In addition, some popular medications' patent expiration may also help drive the market further by encouraging new entrants. During the projected period, these shifting dynamics are expected to increase the ovarian cancer market. In addition, the Major pharmaceutical companies in the region are investing in research and development activities that are expected to boost market growth.

Germany, United Kingdom, Spain, and France are regarded as promising countries with considerable market potential. Ovarian cancer is becoming more common, and it is expected to impact market growth positively. In addition, favorable medical care reforms, increased health awareness, a low-cost basis, and a lack of legal and cultural barriers contribute to the market growth in developed nations are over the forecast period.

In Europe, the United Kingdom has a significant proportion of the ovarian cancer diagnostics and treatments market share. Ovarian cancer is the most common cancer in women in the United Kingdom. Favorable reimbursement policies, advancing the healthcare sector, and infrastructure facilities are most likely to accelerate the market growth in the U.K.

KEY MARKET PLAYERS:

Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.